摘要: Die Therapie der multiplen Sklerose hat sich in den letzten Jahren grundlegend gewandelt. Basierend auf dem wachsenden immunpathogenetischen Verstandnis Erkrankung entstand mit Hilfe modernen Biotechnologie ein wachsendes Arsenal potenzieller Therapeutika, die im Sinne einer „Spezifitatspyramide“ von genereller Immunsuppression bis hin zur spezifischen Blockierung T-Zell-Rezeptor-Peptid-MHC-Komplexen (major histocompatibility complex) erstrecken. Wahrend verschiedene neue Therapeutika nach eingehender klinischer Prufung zugelassen wurden und inzwischen Routinebehandlung MS etabliert sind (Beta-Interferone, Glatirameracetat, Mitoxantron), befindet eine grose Zahl neuer Therapien derzeit Entwicklung.
springer.com
sci-hub.st 参考文章(186)
J S Wolinsky K P Johnson 1, B R Brooks, J A Cohen, C C Ford, J Goldstein, R P Lisak, L W Myers, H S Panitch, J W Rose, R B Schiffer, T Vollmer, L P Weiner, None, Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability Neurology. ,vol. 50, pp. 701- 708 ,(1998) , 10.1212/WNL.50.3.701
M Filippi, M Rovaris, MA Rocca, MP Sormani, JS Wolinsky, G Comi, European/Canadian Glatiramer Acetate Study Group*, Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology. ,vol. 57, pp. 731- 733 ,(2001) , 10.1212/WNL.57.4.731
Derek R. Smith, Konstantin E. Balashov, David A. Hafler, Samia J. Khoury, Howard L. Weiner, Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin‐4 production and associated eosinophilia Annals of Neurology. ,vol. 42, pp. 313- 318 ,(1997) , 10.1002/ANA.410420307
Norbert Ahrens, Abdulgabar Salama, Judith Haas, Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. Journal of Neurology. ,vol. 248, pp. 713- 714 ,(2001) , 10.1007/S004150170122
Ralf Gold, Frank Buttgereit, Klaus V Toyka, Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. Journal of Neuroimmunology. ,vol. 117, pp. 1- 8 ,(2001) , 10.1016/S0165-5728(01)00330-7
JS Wolinsky, PA Narayana, JH Noseworthy, FD Lublin, JN Whitaker, A Linde, P Gjorstrup, HC Sullivan, MRI Analysis Center of the University of Texas–Houston Health Science Center and the North American Linomide Investigators, Linomide in relapsing and secondary progressive MS Part II: MRI results Neurology. ,vol. 54, pp. 1734- 1741 ,(2000) , 10.1212/WNL.54.9.1734
D. Teitelbaum, R. Arnon, M. Sela, Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 96, pp. 3842- 3847 ,(1999) , 10.1073/PNAS.96.7.3842
R. Zivadinov, R. A. Rudick, R. De Masi, D. Nasuelli, M. Ukmar, R. S. Pozzi-Mucelli, A. Grop, G. Cazzato, M. Zorzon, Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS Neurology. ,vol. 57, pp. 1239- 1247 ,(2001) , 10.1212/WNL.57.7.1239
JohnH Noseworthy, MargaretK Vandervoort, Marie Penman, George Ebers, Kenneth Shumak, T Peter Seland, Robin Roberts, Elizabeth Yetisir, Michael Gent, D Wayne Taylor, Cyclophosphamide and plasma exchange in multiple sclerosis. The Lancet. ,vol. 337, pp. 1540- 1541 ,(1991) , 10.1016/0140-6736(91)93226-Y
J. A. Freeman, D. W. Langdon, J. C. Hobart, A. J. Thompson, The impact of inpatient rehabilitation on progressive multiple sclerosis Annals of Neurology. ,vol. 42, pp. 236- 244 ,(1997) , 10.1002/ANA.410420216